Roham Zamanian

Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension

National Heart, Lung, and Blood Institute · R01

PI · $3.7M · University of Pennsylvania

1/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)

National Heart, Lung, and Blood Institute · UG3

Contact PI · $2M · Stanford University

Elafin Therapy for Pulmonary Arterial Hypertension

National Heart, Lung, and Blood Institute · P01

Project lead · $3.8M · Stanford University

Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

Principal investigator · Not yet recruiting · Phase 2

Stanford University

Subcutaneous Elafin in Healthy Subjects

Principal investigator · Completed · Phase 1

Roham T. Zamanian

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

Principal investigator · Completed · Phase 2

Edda Spiekerkoetter

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

Principal investigator · Completed · Phase 4

Stanford University